How 3D Breast CT Is Reshaping Radiology Practice

The Clinical Problem That Standard Mammography Has Never Fully Solved

Mammography has been the backbone of breast cancer screening in the United States for over fifty years. The survival data is real, the infrastructure is mature, and the clinical familiarity is unmatched. But anyone working in breast imaging knows the limitations haven't gone away — they've just become more visible as expectations for diagnostic precision have risen.

Overlapping tissue. Dense parenchyma masking lesions. False positive rates driving unnecessary biopsies and patient anxiety. Recall rates that create downstream costs without proportional clinical benefit. These aren't fringe concerns. They're documented, published, and widely understood within the radiology community.

3D breast CT doesn't pretend those problems don't exist. It addresses them structurally, at the level of physics and acquisition geometry, which is why the clinical conversation around it has matured so significantly over the past several years.

The Physics of Why 2D Falls Short

To understand why 3D breast CT represents a genuine advance rather than incremental improvement, it helps to revisit what makes mammographic interpretation hard.

The breast is a three-dimensional structure being rendered as a two-dimensional image. Structures at different depths are projected onto the same plane, creating superimposition. In a fatty breast, this is manageable — the tissue is relatively homogeneous and low-density. In a dense breast, it becomes a fundamental interpretive challenge. Fibroglandular tissue and malignant masses share similar radiographic density, and their spatial overlap is essentially unsolvable within a 2D acquisition framework.

Tomosynthesis addresses this partially. By acquiring images at multiple angles and reconstructing pseudo-3D slabs, it reduces — but doesn't eliminate — the superimposition problem. The geometry is still planar; the reconstruction is still an approximation.

3D breast CT captures true isotropic volumetric data. Every voxel in the breast volume is resolved independently, with no geometric distortion from projection. The radiologist isn't interpreting a superimposed image — they're navigating actual 3D space.

What Isotropic Resolution Means in Practice

The clinical implications of true isotropic resolution are worth unpacking because they're significant.

With conventional mammography or even tomosynthesis, resolution is anisotropic — finer in the plane of acquisition, coarser in the perpendicular direction. This means that small lesions oriented along certain axes can be missed or mischaracterized.

With 3D breast CT, resolution is equal in all three dimensions — typically sub-millimeter voxels across the entire breast volume. A 4mm spiculated mass that might be partially obscured or distorted in a planar acquisition is fully resolved in all planes. The spiculation pattern, the margins, the relationship to surrounding structures — all of it is visible and measurable.

For radiologists whose workflow involves characterizing BI-RADS 3 and 4 lesions, this level of spatial resolution changes the clinical decision calculus. More confident characterization means fewer unnecessary biopsies. Clearer margins mean more actionable staging information.

The Koning Vera Platform: Purpose-Built for Breast Imaging

The system that has defined the clinical standard for this modality in the US is the Koning Vera 3D breast CT. What distinguishes it clinically from repurposed body CT systems isn't just form factor — it's the entire acquisition and reconstruction pipeline.

Detector geometry is optimized for the breast's specific dimensions and density range. The X-ray spectrum is tuned to maximize contrast between fibroglandular and malignant tissue. Reconstruction algorithms are designed for the specific noise and resolution characteristics of breast anatomy. The result is image quality that purpose-built systems consistently deliver over adapted alternatives.

From an operational perspective, scan time is under ten seconds. Patient positioning is straightforward. The absence of compression removes a significant barrier for certain patient populations and simplifies workflow for technologists. These aren't cosmetic advantages — they have direct implications for throughput, patient compliance, and staffing efficiency.

Dose Considerations in the Context of Screening

Any CT modality in a screening context must answer the dose question clearly. The answer for 3D breast CT is more favorable than many clinicians initially expect.

Mean glandular dose for a dedicated breast ct acquisition on optimized systems is comparable to that of two-view full-field digital mammography — in the range of 3 to 5 mGy for the average breast. For women undergoing supplemental screening due to elevated risk or dense tissue, this dose profile positions 3D breast CT as a clinically defensible alternative to MRI in many scenarios, without the cost, time, or contraindication profile that MRI carries.

The dose comparison to body CT is not the relevant benchmark. Dedicated breast CT systems are designed specifically to minimize dose while maximizing diagnostic yield — the two goals are not in conflict when the acquisition geometry and detector performance are purpose-built for the application.

Integration Into a Tiered Screening Workflow

One of the practical questions facing imaging centers considering adoption is where 3D breast CT fits in the existing screening architecture. The answer depends on patient population and clinical objectives, but several models have emerged in US practice.

For practices serving high proportions of dense-breast patients, 3D breast CT as a primary or co-primary screening modality alongside digital mammography has shown strong recall rate performance. For practices with robust diagnostic workup volume — BI-RADS 0 recalls, known lesion characterization — 3D breast CT as a problem-solving tool reduces the need for additional views, spot compressions, and in some cases targeted ultrasound.

For practices positioned around elevated-risk populations, the comparison to contrast-enhanced MRI is increasingly relevant. 3D breast CT with contrast offers soft tissue characterization competitive with MRI in many clinical scenarios, with substantially lower cost and no claustrophobia or implant contraindication concerns.

Reimbursement and the Adoption Curve

The reimbursement landscape for 3D breast CT in the US is still developing, which is a legitimate operational consideration for practices evaluating the technology. CPT coding exists for dedicated breast CT, and coverage under some commercial payers for specific indications — dense tissue, elevated risk, diagnostic workup — is established in certain markets.

The trajectory is consistent with other emerging imaging modalities that followed a period of limited coverage before widespread adoption. Practices that build clinical volume and outcomes data now are better positioned when broader reimbursement alignment occurs — a pattern that has repeated across multiple imaging technologies over the past two decades.

The Clinical Case Is Already Made

The question in 2026 isn't whether 3D breast CT works. The peer-reviewed literature is substantial, the FDA clearance pathway has been navigated, and the clinical outcomes data from US institutions is consistently supportive.

The operational questions — integration, reimbursement, patient selection, workflow design — are real and worth working through carefully. But they're implementation questions, not validity questions.

For radiologists and imaging center leaders who are serious about diagnostic accuracy, patient experience, and positioning for the next decade of breast imaging, the conversation about 3D breast CT adoption deserves to be on the agenda now, not later.

If you're evaluating 3D breast CT for your practice or institution, connect with a clinical specialist who can walk you through outcomes data, workflow modeling, and reimbursement strategy specific to your patient population and market.